|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kim VN, Han J and Siomi MC: Biogenesis of
small RNAs in animals. Nat Rev Mol Cell Biol. 10:126–139. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Valencia-Sanchez MA, Liu J, Hannon GJ and
Parker R: Control of translation and mRNA degradation by miRNAs and
siRNAs. Genes Dev. 20:515–524. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pang RT, Leung CO, Lee CL, Lam KK, Ye TM,
Chiu PC and Yeung WS: MicroRNA-34a is a tumor suppressor in
choriocarcinoma via regulation of Delta-like1. BMC Cancer.
13:252013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fang CY, Qiu SL, Sun F, Li W, Wang Z, Yue
B, Wu X and Yan D: Long non-coding RNA HNF1A-AS1 mediated
repression of miR-34a/SIRT1/p53 feedback loop promotes the
metastatic progression of colon cancer by functioning as a
competing endogenous RNA. Cancer Lett. 410:50–62. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Corcoran C, Rani S and O'Driscoll L:
miR-34a is an Intracellular and exosomal predictive biomarker for
response to docetaxelwith clinical relevance to prostate cancer
progression. Prostate. 74:1320–1334. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nalls D, Tang SN, Rodova M, Srivastava RK
and Shankar S: Targeting epigenetic regulation of miR-34a for
treatment of pancreatic cancer by inhibition of pancreatic cancer
stem cells. PLoS One. 6:e240992011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Misso G, Di Martino MT, De Rosa G, Farooqi
AA, Lombardi A, Campani V, Zarone MR, Gullà A, Tagliaferri P,
Tassone P and Caraglia M: Mir-34: A new weapon against cancer? Mol
Ther Nucleic Acids. 3:e1942014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hermeking H: The miR-34 family in cancer
and apoptosis. Cell Death Differ. 17:193–199. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yin L, Velazquez OC and Liu ZJ: Notch
signaling: Emerging molecular targets for cancer therapy. Biochem
Pharmacol. 80:690–701. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Artavanis-Tsakonas S, Matsuno K and
Fortini ME: Notch signaling. Science. 268:225–232. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shao S and Zhao X, Zhang X, Luo M, Zuo X,
Huang S, Wang Y, Gu S and Zhao X: Notch1 signaling regulates the
epithelial inverted question markmesenchymal transition and
invasion of breast cancer in a Slug-dependent manner. Mol Cancer.
14:282015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Naik S, MacFarlane M and Sarin A: Notch4
signaling confers susceptibility to TRAIL-induced apoptosis in
breast cancer cells. J Cell Biochem. 116:1371–1380. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bakrania AK, Variya BC, Rathod LV and
Patel SS: DEAE-Dextran coated paclitaxel nanoparticles act as
multifunctional nano system for intranuclear delivery to triple
negative breast cancer through VEGF and NOTCH1 inhibition. Eur J
PharmBiopharm. 122:37–38. 2018. View Article : Google Scholar
|
|
17
|
Lakhani SR, Ellis IO, Schnitt SJ, Tan PH
and van de Vijver MJ: WHO Classification of Tumours of the Breast.
4th. Lyon: IARC Press; 2012
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu M, Li D, Yang C and Ji JS: MicroRNA-34a
Inhibition of the TLR signaling pathway via CXCL10 suppresses
breast cancer cell invasion and migration. Cell Physiol Biochem.
46:1286–1304. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
He R, Liu P, Xie X, Zhou Y, Liao Q, Xiong
W, Li X, Li G, Zeng Z and Tang H: circGFRA1 and GFRA1 act as ceRNAs
in triple negative breast cancer by regulating miR-34a. J Exp Clin
Canc Res. 36:1452017. View Article : Google Scholar
|
|
21
|
Xia Y, Deng XW, Cao MJ, Liu S, Zhang X,
Xiao X, Shen S, Hu Q and Sheng W: Nanodiamond-based layer-by-layer
nanohybrids mediate targeted delivery of miR-34a for triple
negative breast cancer therapy. RSC Adv. 8:13789–13797. 2018.
View Article : Google Scholar
|
|
22
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulationin human breast cancer.
Cancer Res. 65:7065–7070. 2015. View Article : Google Scholar
|
|
23
|
Volinia S, Galasso M, Sana ME, Wise TF,
Palatini J, Huebner K and Croce CM: Breast cancer signatures for
invasiveness and prognosis defined by deep sequencing of microRNA.
Proc Natl Acad Sci USA. 109:3024–3029. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hoshino I and Matsubara H: MicroRNAs in
cancer diagnosis and therapy: From bench to bedside. Surg Today.
43:467–478. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Suman S, Das TP and Damodaran C: Silencing
NOTCH signaling causes growth arrest in both breast cancer stem
cells and breast cancer cells. Br J Cancer. 109:2587–2596. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pan H, Zhou W, He W, Liu X, Ding Q, Ling
L, Zha X and Wang S: Genistein inhibits MDA-MB-231 triple-negative
breast cancer cell growth by inhibiting NF-κB activity via the
Notch-1 pathway. Int J Mol Med. 30:337–343. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ma ZL, Hou PP, Li YL, Wang DT, Yuan TW,
Wei JL, Zhao BT, Lou JT, Zhao XT, Jin Y and Jin YX: MicroRNA-34a
inhibits the proliferation and promotes the apoptosis of non-small
cell lung cancer H1299 cell line by targeting TGFβR2. Tumour Biol.
36:2481–2490. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gougelet A, Sartor C, Bachelot L, Godard
C, Marchiol C, Renault G, Tores F, Nitschke P, Cavard C, Terris B,
et al: Antitumour activity of an inhibitor of miR-34a in liver
cancer with beta-catenin-mutations. Gut. 65:1024–1034. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang X and Zhao X, Shao S, Zuo X, Ning Q,
Luo M, Gu S and Zhao X: Notch1 induces epithelial-mesenchymal
transition and the cancer stem cell phenotype in breast cancer
cells and STAT3 plays a key role. Int J Oncol. 46:1141–1148. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bolos V, Mira E, Martinez-Poveda B, Luxán
G, Cañamero M, Martínez-A C, Mañes S and de la Pompa JL: Notch
activation stimulates migration of breast cancer cells and promotes
tumor growth. Breast Cancer Res. 15:R542013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lai M, Du G, Shi R, Yao J, Yang G, Wei Y,
Zhang D, Xu Z, Zhang R, Li Y, et al: miR-34a inhibits migration and
invasion by regulating the SIRT1/p53 pathway in human SW480 cells.
Mol Med Rep. 11:3301–3307. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liang J, Li Y, Daniels G, Sfanos K, De
Marzo A, Wei J, Li X, Chen W, Wang J, Zhong X, et al: LEF1
targeting EMT in prostate cancer invasion is regulated by miR-34a.
Mol Cancer Res. 13:681–688. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yu G, Yao W, Xiao W, Li H, Xu H and Lang
B: MicroRNA-34a functions as an anti-metastatic microRNA and
suppresses angiogenesis in bladder cancer by directly targeting
CD44. J Exp Clin Cancer Res. 33:7792014. View Article : Google Scholar : PubMed/NCBI
|
